Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Head Office Relocation,Research Facility Expansion

19 Jul 2013 07:00

RNS Number : 6779J
Plant Health Care PLC
19 July 2013
 



19 July 2013

 

PLANT HEALTH CARE PLC

 

Plant Health Care relocates head office and expands research facilities

 

Plant Health Care (AIM/CISX: PHC.L), a leading provider of naturally derived products to the agriculture industry, announces that it is relocating its headquarters from Pittsburgh, PA to Raleigh, NC. The relocation will take place during the remainder of 2013, with completion of the transition by the end of this year. 

 

The company is also significantly increasing its research activities and personnel. The research facilities have now moved from their previous location to a much-expanded office and laboratory facility in the Seattle, WA area. The new facilities are approximately four times the size of the previous location and will accommodate additional senior scientists and technicians.

 

Dr. Christopher Richards, Chairman of Plant Health Care commented on the head office relocation: "The Board and Shareholders of Plant Health Care concluded that relocating the headquarters of the company to one of the major global agriculture industry communities was in the best interests of the company. North Carolina is home to a number of leading agriculture players and offers world-class infrastructure, workforce and resources for our business."

 

Paul Schmidt, CEO of Plant Health Care commented on the research expansion: "Our recent successful placing enables us to ramp-up our research activities significantly over the next few years. The primary focus of this enhanced effort will be the continued discovery and development of the Harpin technology platform, driven by the current commercial success of Harpin alpha-beta and by very promising early results with third generation products."

 

Dr. Zhongmin Wei, Vice President and Chief Science Officer of Plant Health Care commented: "The expansion of the research investment and activities is an exciting development for Plant Health Care. We have developed a remarkable platform of technology and intellectual property and the opportunity to continue expanding and accelerating this development is extremely exciting. I have been involved in the development of Plant Health Care's technology for a long time and am thrilled with the opportunity to take this platform to the next level."

 

- ENDS-

 

About Plant Health Care, plc: Plant Health Care, plc ("PHC") is a leading provider of naturally derived products for plants and soil. The Company's ordinary shares have been quoted on the Alternative Investment Market ("AIM") of the London Stock Exchange since July 2004 and listed on the Official List of the Channel Islands Stock Exchange ("CISX") in February 2010 (ticker symbol/ mnemonic: PHC).

 

PHC's products are aimed at agriculture industries and are environmentally beneficial. Through the commercialisation of these products, PHC is capitalising on current long-term trends toward natural systems and biological products for plant care and soil and water management.

 

Further information is available at: www.planthealthcare.com or please contact:

 

 

Plant Health Care plc
 
Paul Schmidt, Chief Executive Officer
Tel: +1-412-826-5488
Stephen Weaver, Finance Director
Tel: +1-412-826-5488
 
 
Nomura Code Securities
 Tel: +44 (0) 20 7776 1200
Clare Terlouw / Chris Golden
 
 
 
Powerscourt
Tel: +44 (0) 20 7250 1446
Paul Durman / Nick Dibden / Sophie Moate
 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAGMGMNGRVGFZZ
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.